BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:REGV131-LNP1265 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of REGV131-LNP1265\, from ClinicalTrials.gov
  estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06379789-11306@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20340814
DTEND;VALUE=DATE:20340815
SUMMARY:REGV131-LNP1265: Phase 1/2 readout est. (NCT06379789)
DESCRIPTION:REGV131-LNP1265\, phase 1/2\, Hemophilia B.\nStudy: A Study to 
 Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene I
 nsertion Therapy (REGV131-LNP1265) in Pediatric\, Adolescent and Adult Par
 ticipants With Hemophilia B\nEstimated primary completion: 14 August 2034.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/regv131-lnp1265#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06379789
URL:https://assetmemo.bio/drug/regv131-lnp1265#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
